Proteomics and recombinant antigen synthesis

The company has over 750 customers in Europe. Currently, almost all of its revenue is derived from outsourced products, but the company is moving to change that and introduce products developed in-house. InGen BioSciences will be developing proprietary in vitro diagnostic kits based on its specialist knowledge in proteomics and expertise in synthesising new recombinant antigens. These innovative diagnostic kits will fill unmet needs in detecting the presence or absence of bacterial infections, such as coagulase-negative staphylococci and streptococci, in artificial joint replacements in pre- and post-operative implants. Ingen BioSciences plans to achieve its new product development through patent-generating R&D, multiplex test development and alliances with firms providing complementary technologies
www. ingen.fr